RESEARCH

Cytotoxicity, acute and sub-chronic toxicities of the leaves of *Bauhinia thonningii* (Schumach.) Milne-Redh. (Caesalpiniaceae)

Valaire Y. Matieta[1], Armelle T. Mbaveng[1,2], Guy R. Sado Nouemsi[3], Simplice B. Tankeo[1], Gabriel T. Kamsu[1], Paul Nayim[1], Alain M. Lannang[3], İlhami Çelik[4], Thomas Efferth[2*] and Victor Kuete[1,2*]

Abstract

Background *Bauhinia thonningii* is a plant traditionally used against many human diseases such as gastric ulcers, fever, inflammations, coughs, dysentery, diarrhea, and malaria. In the present investigation, the cytotoxicity of methanol extract of *Bauhinia thonningii* leaves (BTL), fractions and the isolated phytoconstituents was determined in a panel of 9 human cancer cell lines including drug sensitive and multidrug-resistant (MDR) phenotypes. The acute and sub-chronic oral toxicity of BTL was investigated as well.

Methods Compounds were isolated using chromatographic techniques while their chemical structures were determined using spectroscopic methods. The resazurin reduction assay (RRA) was used to evaluate the cytotoxicity of samples, propidium iodide (PI) for apoptosis, 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) staining for mitochondrial membrane potential (MMP) analysis, 2´,7´-dichlorodihydrofluoresceine diacetate (H2DCFH-DA) staining for the quantification of reactive oxygen species (ROS), whereas Caspase Glo assays were combined by means of flow cytometry. Furthermore, the toxicological investigations were performed as recommended by the Organization for Economic Cooperation and Development (OECD).

Results The botanicals as well as 6-C-methylquercetin-3,7-dimethyl ether (2), quercetin-3-*O*-$_L$-rhamnopyranoside (5), quercetin-3-*O*-β-glucopyranoside (6), 6,8-C-dimethylkaempferol 3,7-dimethyl ether (7), and 6,8-C-dimethylkaempferol-3-methyl ether (8) had promising cytotoxic effects in the 9 tested cancer cell lines. The IC_{50} values below 20 µg/mL (botanicals) or 10 µM (compounds) on at least 1/9 tested cancer cell lines were considered. The best cytotoxic effects with IC_{50} values below 5 µM were achieved with compounds 7 against CEM/ADR5000 leukemia cells (2.86 µM) and MDA-MB-231-*pcDNA* breast adenocarcinoma cells (1.93 µM) as well as 8 against CCRF-CEM leukemia cells (3.03 µM), CEM/ADR5000 cells (2.42 µM), MDA-MB-231-*pcDNA* (2.34 µM), and HCT116 *p53*$^{-/-}$ cells (3.41 µM). BTL and compound 8 induced apoptotic cell death in CCRF-CEM cells through caspase activation, alteration of MMP, and increased ROS production. BTL did not cause any adverse effects in rats after a single administration at 5000 mg/kg or a repeated dose of 250 mg/kg body weight (b. w.).

Conclusion *Bauhinia thonningii* and its constituents are sources of cytotoxic drugs that deserve more in-depth studies to develop novel antiproliferative phytomedicine to fight cancer including resistant phenotypes.

*Correspondence:
Thomas Efferth
efferth@uni-mainz.de
Victor Kuete
kuetevictor@yahoo.fr
Full list of author information is available at the end of the article

Matieta *et al. BMC Complementary Medicine and Therapies* (2023) 23:341

Page 2 of 20

Background

Cancer remains one of the world's biggest threats with an alarming mortality rate placing it among the major categories of public health problems. Malignancies were responsible for around 10 million deaths worldwide in 2020 [1]. The mortality rate in Africa is estimated at up to 700,000 deaths/year [1]. According to forecasts, cancer mortality will increase considerably reaching a milestone of one million deaths per year by 2030 in case of absence of drastic and conclusive measures [2]. Its recessive resistance to current treatments such as chemotherapy, radiotherapy, and surgery is due to the ability of malignant cells to form tumors with metastatic potential and mechanisms of resistance to standard chemotherapeutics [3]. Medicinal plants are proving to be a potential source for their widespread use in the traditional medicine with over 80% of people in Sub-Saharan Africa resorting to medicinal plant treatments [2, 4]. In addition, plants have been shown in numerous studies to be a potential source of bioactive molecules against various species of multidrug-resistant (MDR) and susceptible bacteria, fungi, viruses, susceptible and MDR cancer lines as well as against diabetes, hypertension, and obesity [5–10]. During a pandemic like that of COVID-19, the use of plants by the African population has proven to be lifesaving and has been an effective solution in the management of this disease. However, questions arise about the anarchic use, which supports the idea of the World Health Organization (WHO) on the safety of the use of plants and, consequently, the toxic and undesirable effects it may cause [11]. *Bauhinia thonningii* (Schumach.) Milne-Redh. (Caesalpiniaceae) is a medicinal plant used in the traditional medicine in the treatment of several pathologies such as dysentery, fever, respiratory ailments, snake bites, hookworm, skin diseases, male erectile malfunction, gastrointestinal track problems, inflammation, bilharzia, eye diseases, malaria, and catarrh [12, 13]. It has been recommended that plants used traditionally against immune and skin disorders, inflammations as well as microbial, parasitic, and viral infections should be screened for cancer drug discovery as these diseases bear reference to cancer or cancer-like symptoms [14, 15]. This is the rationale for investigating the cytotoxic potential of this plant. The study was extended to the isolation of the cytotoxic constituent and the toxicological survey of the leaf's methanol extract of the plant. Previous studies have shown that this plant possesses several pharmacological activities. In effect, Abdelwahab and collaborators have demonstrated the gastroprotective effects of the methanol and chloroform extracts of the leaves of *Bauhinia thonningii* leaves on ethanol-induced gastric ulceration in Sprague Dawley rats [16]. They showed that the gastroprotective mechanism of the botanical was mediated by the modulation of Periodic acid-Schiff reactive substances, malondialdehyde, and proteomics biomarkers such as creatine kinase, malate dehydrogenase, ATP synthase, actin, and thioredoxin [16]. This plant also displayed hyaluronidase, phospholipase A2 and protease inhibitory activity, indicating the potential against the necrosis-inducing enzymes of snake venom [17]. The leaf extract of this plant displayed antimicrobial activities against *Escherichia coli, Staphylococcus aureus, Enterobacter* species, *Streptococcus pneumoniae, Corynebacterium pyogenes, Enterococcus faecalis, Acinetobacter* species, *and Pseudomonas aeruginosa* [18]. Moreover, the investigation of the antibacterial activity of the plant led to the identification of 6-C-methylquercetin-3,4'-dimethyl ether which displayed prominent inhibitory effects against the resistant phenotypes of Gram-negative bacterium *Klebsiella pneumoniae* and the Gram-positive bacterium *Staphylococcus aureus* [13]. The hypoglycemic and anti-hyperglycemic properties of the plant was also demonstrated in rats [19]. Various leaf extracts of this plant had hypoglycemic effect through their ability to reduce fasting blood glucose in alloxan-induced diabetic rats [20]. The antiviral activity of the leaves of this plant has also been reported against poliovirus, astrovirus, herpes simplex viruses, and parvovirus [21]. Leaf extract of this plant also displayed antioxidant effect through exhibited 2, 2-dipheny l-picrylhydrazyl (DPPH) and (2,2'-azino-bis-(3-ethylbenzothiazolin-6-sulfonic acid) (ABTS) scavenging activities [22].

Methods

Plant material and extraction

The leaves of *Bauhinia thonningii* (Schumach.) Milne-Redh. (Caesalpiniaceae) were collected in Bandjoun (5°21′N 10°24′E) in the West region of Cameroon. This plant is not an endangered species, and it was collected in open community field and therefore no prior permission was required. The plant parts (leaves, bark) and the whole plant were identified in the Cameroon National Herbarium (HNC) under the voucher code 33,258/HNC, and furthermore, the plant name *Bauhinia thonningii* (Schumach.) Milne-Redh. (Caesalpiniaceae) was further authenticated using the plant index database, *the*

World Flora Online, under the reference code WFO-0001054410. The leaves were dried and powdered, and 2.0 kg were soaked in 15 L of methanol (CH_3OH) for 48 h. The filtrate obtained using Whatman filter paper grade 1 was evaporated under vacuum to obtain 200.4 g of the crude methanol extract or the botanical (BTL). The botanical was stored at 4 °C for further use.

Isolation and purification

Part of BTL (194.0 g) was triturated with ethyl acetate (EtOAc) to obtain 96.2 g of EtOAc fraction (BTLa) and 78.3 g of residue (BTLb). The two fractions displayed cytotoxic effects in cancer cell lines and were further subjected to purification. Ninety-six grams (96.0 g) of the BTLa were subjected to column chromatography (CC) using silica gel and eluted with a gradient of *n*-hexane–EtOAc (100:0 to 0:100, v/v) and EtOAc-CH_3OH (100:0 to 0:100, v/v) to obtain 168 sub-fractions (sub-frs) of 300 mL each collected as follows: *n*-hexane–EtOAc 100:0 (sub-frs 1–24); *n*-hexane–EtOAc 95:5 (sub-frs 25–47); *n*-hexane–EtOAc 85:15 (sub-frs 48–84); *n*-hexane–EtOAc 75:25 (sub-frs 85–108); *n*-hexane–EtOAc 40:60 (sub-frs 109–117); *n*-hexane–EtOAc 25:75 (sub-frs 118–132); EtOAc-CH_3OH 100:0 (sub-frs 133–144); EtOAc-CH_3OH 90:10 (sub-frs 145–160), and EtOAc–MeOH 0:100 (sub-frs 161–168). Based on their TLC profiles, these fractions were pooled into seven major sub-fractions (A-G) as follows: sub-fractions A (0% *n*-hexane–EtOAc, sub-frs 1–22, 10.2 g), B (0%-15% *n*-hexane–EtOAc, sub-frs 23–62, 7.5 g), C (15%-25% *n*-hexane–EtOAc, sub-frs 63–85, 8.0 g), D (25%-75% *n*-hexane–EtOAc, sub-frs 86–125, 25.7 g), E (75%-100% *n*-hexane–EtOAc, sub-frs 126–137, 10.5 g), F (0%-10% EtOAc-CH_3OH, sub-frs 138–155, 5.7 g), and G (10%-100% EtOAc-CH_3OH, sub-frs 156–168, 6.5 g). Sub-fractions A and B contained mainly fatty acids and were not further investigated. Compounds 4 (15.1 mg) and 9 (19.9 mg) precipitated from fraction C (2.1 g), while compound 10 (25.0 mg) precipitated from fraction E, obtained after simple filtration with EtOAc. Fraction D was subjected to repeated silica gel CC using a gradient elution of *n*-hexane–EtOAc (100:0 to 50:50, v/v) to afford 75 sub-frs of 75 mL each as follows: *n*-hexane–EtOAc 95:5 (sub-frs 1–33), *n*-hexane–EtOAc 85:15 (sub-frs 34–49), *n*-hexane–EtOAc 70:30 (sub-frs 50–63), and *n*-hexane–EtOAc 50:50 (sub-frs 64–75). Based on their TLC profiles, sub-fractions 44–48 and 50–51 were pooled separately and identified as a mixture of compounds, whereas other sub-fractions obtained in a very small amount were not further investigated. The mixture of compounds was treated and purified by CC over Sephadex LH-20 eluting with CH_2Cl_2-CH_3OH (50:50), v/v to yield compound 1 (9.9 mg) from sub-frs 44–48, as well as 2 (12.1 mg) and 8 (6.1 mg) from sub-frs 50–51.

The fraction BTLb (77.0 g) was subjected to repeated silica gel CC using a gradient elution of *n*-hexane–EtOAc (100:0 to 0:100, v/v) and EtOAc-CH_3OH (100:0 to 10:90, v/v) to afford 67 sub-frs of 200 mL each collected as follows: *n*-hexane–EtOAc 100:0 (sub-frs 1–7), *n*-hexane–EtOAc 85:15 (sub-frs 8–24), *n*-hexane–EtOAc 75:25 (sub-frs 25–30), *n*-hexane–EtOAc 60:40 (sub-frs 31–40), EtOAc-CH_3OH 100:0 (sub-frs 41–55), and EtOAc-CH_3OH 90:10 (sub-frs 56–67). Based on their TLC profiles, these sub-frs were pooled together into the five major sub-frs (I-V) as follows: I (0%-15% *n*-hexane–EtOAc, sub-frs 1–23, 8.0 g), II (15%-25% *n*-hexane–EtOAc, sub-frs 24–28, 7.5 g), III (25%-40% *n*-hexane–EtOAc, sub-frs 29–40, 12.0 g), IV (100% EtOAc, sub-frs 41–47, 30.7 g), and V (0%-10% EtOAc-CH_3OH, sub-frs 48–67, 10.5 g). A precipitate in powder form was observed from fractions II-IV. After simple filtration and purification with ethyl acetate, compounds 7 (8.1 mg), 3 (11.1 mg), and mixture were obtained from fractions II, III, and IV, respectively. The separation of a mixture was possible after CC over Sephadex LH-20 eluting with CH_2Cl_2-CH_3OH (50:50), v/v to afford compounds 5 (15.9 mg) and 6 (17.2 mg).

Cancer cell lines and cell culture

In this study, a panel of 9 cancer cell lines as well as the normal AML12 hepatocytes were used. The source of these cell lines has been elucidated earlier [23]. The drug-sensitive CCRF-CEM and its multidrug-resistant P-glycoprotein (P-gp)-overexpressing subline, CEM/ADR5000 have been previously reported [24–26]. The sources of the HepG2 hepatocarcinoma [27], U87MG glioblastoma cells and its resistant epidermal growth factor receptor (EGFR) transfected subline, U87MG.*ΔEGFR* [28], HCT116 *p53*[+/+] colon adenocarcinoma cells and its resistant knock-out congener, HCT116 *p53*[−/−] [29], MDA-MB-231-*pcDNA3* breast adenocarcinoma cells and its multidrug-resistant breast cancer resistance protein (BCRP)-transfected MDA-MB-231-*BCRP* clone 23 subline [30] have also been described. To compare the activity of samples in HepG2 cells, the AML12 hepatocytes were used [31]. The cell culture media used included RPMI-1640 for CCRF-CEM cells and CEM/ADR5000 cells as well as DMEM for other (adherent) cells. These culture media were used as complete media with additional 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen, Eggenstein, Germany). To maintain their resistance patterns, CEM/ADR5000 cells were cultured in a complete medium with additional 5000 ng/mL doxorubicin whereas MDA-MB-231-*BCRP*, HCT116 *p53*[−/−], and U87MG.*ΔEGFR* cells were cultured in a complete medium with additional geneticin at 800 ng/mL and 400 μg/mL, respectively [32, 33].

Matieta *et al. BMC Complementary Medicine and Therapies*   (2023) 23:341

Page 4 of 20

Cytotoxicity evaluation

To determine the cytotoxicity of the botanicals (BTL, BTLa, and BTLb), phytoconstituents (1–10) as well as the positive control, doxorubicin, the resazurin reduction-based assay (RRA) was used as earlier described [34] under experimental conditions applied previously [27, 33]. Botanicals were tested in the concentration range of 0.63–80 μg/mL, the isolated compounds at 0.78—100 μM; the treated cells were incubated for 72 h; the fluorescence was measured at the excitation wavelength of 544 nm and at the emission wavelengths of 590 nm using Infinite M2000 Pro™ plate reader (Tecan, Crailsheim, Germany). The data were expressed as IC_{50} values of tested samples defined as the concentration required to inhibit 50% of the cell proliferation. They were deduced from a calibration curve by linear regression from Microsoft Excel [35]. The degree of resistance (D. R.) of cancer cells towards the investigated samples was determined as the ratio of the IC_{50} value in the resistant cell line *versus* IC_{50} value in the corresponding sensitive cell line [36, 37]; the ratio of the IC_{50} value of the normal AML12 hepatocytes *versus* that of HepG2 cells was referred to as the selectivity index (S.I.) [38].

Analysis of cell cycle distribution and apoptosis

The distribution of the cell cycle in CCRF-CEM cells as a result of the application of the botanical BTL, compound 8, doxorubicin, or solvent control, dimethyl sulfoxide (DMSO) was evaluated by the combined flow cytometry and propidium iodide staining similarly to the previously reported experimental conditions [39]. The concentrations of samples used to treat the CCRF-CEM cells were 0.25, 0.5, 1, and 2 folds the IC_{50}. The treated cells (1 mL; 1×10^6 cells) were incubated for 24 h at 37 °C, 5% CO_2 and 95% relative humidity referred to as the standard cell culture condition. The cell cycle analysis was further monitored by means of the BD Accury C6 Flow Cytometer (BD Biosciences, Heidelberg, Germany) [39, 40]. Assays were performed separately at least three times in triplicates.

Analysis of apoptosis by the combined annexin V/ propidium iodide staining and flow cytometry

To detect the apoptotic CCRF-CEM cells resulting from the application of BTL, compound 8, doxorubicin, or DMSO, the annexin V/propidium iodide (PI) staining combined with the flow cytometry was used in similar experimental conditions as reported earlier [33, 41–43]. The concentration of samples used and CCRF-CEM cells were those as reported above under the standard cell culture conditions. To detect the apoptotic cells, the fluorescein isothiocyanate (FITC)-conjugated annexin V/PI assay kit (eBioscience™ Annexin V; Invitrogen, San Diego, USA) was applied to treated cells after 24 h incubation followed by the measurements with BD Accury C6 Flow Cytometer (BD Biosciences) [42, 43]. The assays were performed separately three times and in triplicate.

Caspases activity evaluation by the combined Caspase-Glo assay and spectrophotometry

To detect the activity of caspases in CCRF-CEM cells resulting from the application of BTL and compound 8, the Caspase-Glo assay combined with the spectrophotometric determination of their luminescence was applied in similar experimental conditions as reported earlier [44]. The concentrations of samples used to treat the CCRF-CEM cells were 0.25, 0.5, 1, and 2 folds the IC_{50}. The amount of the treated cells was 1.5×10^4 cells for the caspase 3/7 assay or 3×10^4 cells for the caspase 8 and caspase 9 assays in 100 μL. The treated cells were then incubated for 6 h under the standard cell culture conditions as described above. Subsequently, the activity of caspases was detected by a spectrophotometry measurement of luminescence using 100 μL caspase solution from the Caspase-Glo 3/7, 8, and 9 Assay kits (Promega, Mannheim, Germany) with an Infinite M2000 ProTM plate reader (Tecan).

Assessment of MMP alteration and ROS production

To quantify the modification of the mitochondrial membrane potential (MMP) and the reactive oxygen species (ROS) production in CCRF-CEM cells resulting from the application of BTL, either compound 8 or DMSO (negative control), or the respective positive controls for MMP or ROS evaluations, valinomycin or H_2O_2 (Sigma-Aldrich, Taufkirchen, Germany), the 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide (JC-1; Biomol, Hamburg, Germany) staining and the 2′,7′-dichlorodihydrofluorescein diacetate (H_2DCFH-DA) (Sigma-Aldrich) staining, respectively for MMP and ROS measurements, were combined with the flow cytometry used in similar experimental conditions, as earlier reported [45]. The concentrations of samples used to treat the CCRF-CEM cells were 0.25, 0.5, 1, and 2 folds the IC_{50}. The treated cells (1 mL; 1×10^6 cells) were incubated for 24 h under the standard cell culture condition. Cells were further stained for 30 min with 10 μL of staining solution (JC-1 for ROS evaluation or H_2DCFH-DA solution for ROS evaluation) according to the manufacturer's protocol. Using the LSRFortessa FACS analyzer (Becton–Dickinson, Heidelberg, Germany), the amount of 1×10^4 cells was further measured as described earlier [31, 45–47].

Animal experimentation in toxicological studies

Thirty-eight *Wistar* albino rats at 8 weeks of age weighting between 160 and 200 g were investigated. The animal breeding took place in the animal house, University of Dschang, Cameroon. The animals were placed individually in polypropylene cages at 25 ± 1 °C in a 12 h: 12 h dark: light cycle. Food and tap water were given to them ad libitum. The animals were treated according to the protocol for the care and use of laboratory animals based on the ethical considerations of the Institutional Ethical Committee of the University of Dschang, Cameroon (Project No. BCH1202/FS/UDS/2020).

Acute oral toxicity of BTL

The acute toxicity study was conducted according to the OECD guideline with six healthy female rats (age: 8 weeks; mass: 150–155 g). They were nulliparous [48] and were randomly divided into two groups of three rats per group. Group I was the control group whereas Group II received a dose of 5000 mg/kg of BTL one after another and in a time interval of 48 h. Each animal received the extract by gavage using an endogastric tube. The trial ended when the three serial rats survived to a limited dose of 5000 mg/kg. After the administration of the test extract (BTL), mortality and clinical signs were noted for the first 3 h and thereafter for 14 days of drug administration [49]. After 14 days of observation, animals were anesthetized with diazepam/ketamine (0.2/0.1 mL per 100 g of the animal) association and autopsied. Eventual macroscopic changes were observed in organs such as the liver, kidneys, lungs, and heart.

Sub-chronic oral toxicity study of BTL

The sub-chronic oral toxicity study was conducted according to the standard methods [50] with thirty-two (32) rats (16 males and 16 females; age: 8 weeks; mass: 180–200 g) randomly divided into 4 groups of 4 rats per group and sex. The rats received BTL at 250 mg/kg, 500 mg/kg, and 1000 mg/kg doses of body weight (b. w.) by endogastric gavage for 28 days in batches 1, 2, and 3, respectively. Batch 4 was the control group for each sex. Food consumption and body weight were determined every four days, as previously described [51]. On day 29 of the test, after gavages, the animals were subjected to a 12 h food fast, at the end of which urine was collected. Subsequently, the animals were sacrificed and autopsied. The sacrifice was done as follows: the rats were anesthetized with intra-peritoneal injections of diazepam (0.1 mL/100 g of the animal) and ketamine (0.2 mL/100 g of the animal). The blood was collected by cardiac puncture and then first introduced into a tube containing an anticoagulant, ethylenediaminetetraacetic acid (EDTA), for the hematological analysis using QBC Autoread Plus (Ipswich, United Kingdom) and, secondly, into a tube without anticoagulant for the preparation of the serum. The serum obtained was used to determine biochemical parameters such as creatinine, urea, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, and total proteins using commercial SPINREACT brand kits (Barcelona, Spain). After that, certain organs such as the heart, kidneys, liver, lung, and spleen were immediately removed. These organs were used to determine the relative weight of the organs. One part of each organ for histopathological analysis was stored in 10% buffered formalin, as described earlier [52].

Statistical analysis

Statistical analyses were performed using SPSS version 23.0 for Windows. The results were expressed as mean value ± standard deviation (SD), and the comparisons were performed by the analysis of variance using a one-way analysis of variance test. Differences between the averages of control and drug-treated groups where they existed were separated using the Waller–Duncan test. *P*-values less than 0.05 were considered statistically significant.

Results

Phytochemistry

The phytochemical study of *Bauhinia thonningii* led to the isolation and identification of 10 compounds. Their chemical structures are shown in Fig. 1. The general experimental procedure is provided in Supplementary Information S1 whereas their spectral properties including ^{1}H NMR, ^{13}C NMR, and HMBC data are shown in Supplementary Information S2. The phytochemicals were identical to those previously described in the literature. They were six flavonols: 6-C-methylquercetin-3,4'-dimethyl ether $C_{18}H_{16}O_7$ (1; yellow powder; *m/z* 345.09; m. p. 195–197 °C) [13], 6-C-methylquercetin-3,7-dimethyl ether $C_{18}H_{16}O_7$ (2; yellow powder; *m/z* 344.32; m. p. 195–197 °C) [13, 53], 6-C-methylquercetin 3,7,3'-trimethyl ether $C_{19}H_{18}O_7$ (3; yellow powder; *m/z* 344.32; m. p. 185–187 °C) [13, 53], quercetin $C_{15}H_{10}O_7$ (4; yellow powder; *m/z* 302.24; m. p. 314–317 °C) [53], 6,8-C-dimethylkaempferol 3,7-dimethyl ether $C_{19}H_{18}O_6$ (7; yellow powder; *m/z* 342.35; m. p. 285–287 °C) [13, 53], and 6,8-C-dimethylkaempferol-3-methyl ether $C_{18}H_{16}O_6$ (8; yellow powder; *m/z* 228.09; m. p. 250–253 °C) [13, 53]; two flavonol glycosides: quercetin-3-*O*-$_L$-rhamnopyranoside $C_{21}H_{20}O_{11}$ (5; yellow powder; *m/z* 448.10; m. p. 180–182 °C)[13, 53], and quercetin-3-*O*-*β*-glucopyranoside $C_{21}H_{20}O_{12}$ (6; yellow powder; *m/z* 464.38; m. p. 176–179 °C) [13, 53], one triterpenoids ursolic acid $C_{30}H_{48}O_3$ (9; white powder; *m / z* 456.71; m. p. 283–285 °C)[13, 54],

Matieta *et al. BMC Complementary Medicine and Therapies*   (2023) 23:341

Page 6 of 20

Fig. 1 Chemical structures of compounds isolated from the leaves of *Bauhinia thonningii*. 6-C-methylquercetin-3, 4'-dimethyl ether (1); 6-C-me thylquercetin-3,7-dimethyl ether (2); 6-C-methylquercetin 3,7,3'-trimethyl ether (3); quercetin (4); quercetin-3-*O*-_L_-rhamnopyranoside (5); quercetin-3-*O*-*β*-glucopyranoside (6); 6,8-C-dimethylkaempferol 3,7-dimethyl ether (7); 6,8-C-dimethylkaempferol-3-methyl ether (8); ursolic acid (9); 3-*O*-*β*-_D_-glucopyranoside of *β*-sitosterol (10)

and one sterol glycoside, 3-*O*-*β*-_D_-glucopyranoside of *β*-sitosterol $C_{35}H_{60}O_6$ (10; white powder; *m / z* 456.71; m. p. > 212 ℃) [13, 55]. These compounds were tested alongside the botanicals towards a panel of human cancer cell lines, and the results are shown in Table 1.

Cytotoxicity of the studied samples

The data on the cytotoxicity of BTL, BTLa, BTLb, and doxorubicin are displayed in Tables 2 and 3. The three botanicals including the crude extract BTL as well as the fractions BTLa and BTLb had cytotoxic effects towards

Table 1 Cytotoxicity of the methanol extract (BTL), fractions (BTLa and BTLb) from the leaves of *Bauhinia thonningii* as well as doxorubicin in the studied cancer cells

Cell lines	Samples, IC$_{50}$ values in µg/mL or µM (for Doxorubicin), degrees of resistance[a] or selectivity index[b] (in bracket)			
	Methanol extract	Fractions	Positive control	
	BTL	BTLa	BTLb	Doxorubicin
CCRF-CEM	**18.13 ± 1.42**	**19.51 ± 0.96**	**17.05 ± 1.03**	**0.02 ± 0.00**
CEM/ADR5000 Degree of resistance[a]	29.20 ± 1.77 (1.61)	**19.16 ± 1.68** (0.98)	23.49 ± 2.31 (1.37)	122.96 ± 10.94 (6,683.00)
MDA-MB-231-*pcDNA*	23.09 ± 2.19	**17.76 ± 2.01**	24.76 ± 1.93	**0.13 ± 0.01**
MDA-MB-231-*BCRP* Degree of resistance	26.22 ± 1.61 (1.14)	20.08 ± 0.89 (1.13)	64.74 ± 3.82 (2.61)	**0.79 ± 0.08** (6.14)
HCT116 *p53*$^{+/+}$	40.84 ± 3.12	43.60 ± 2.55	52.33 ± 3.71	**0.48 ± 0.06**
HCT116 *p53*$^{-/-}$ Degree of resistance	28.14 ± 1.83 (0.70)	47.40 ± 3.28 (1.08)	48.91 ± 2.89 (0.93)	**1.78 ± 0.08** (3.73)
U87MG	22.66 ± 1.76	**12.46 ± 0.67**	16.55 ± 1.40	**0.26 ± 0.03**
U87MG.Δ*EGFR* Degree of resistance	24.43 ± 0.89 (1.07)	**15.61 ± 1.72** (1.25)	29.05 ± 1.99 (1.21)	**0.98 ± 0.07** (3.79)
HepG2	24.38 ± 1.26	**18.30 ± 0.77**	30.65 ± 2.16	**4.56 ± 0.48**
AML12 Selectivity index[b]	70.12 ± 3.25 (2.87)	> 80 (4.37)	> 80 (2.61)	> 50 (> 11.59)

[a] The degree of resistance was determined as the ratio of IC$_{50}$ value in the resistant divided by IC$_{50}$ in the sensitive cell line; CEM/ADR5000 *versus* CCRF-CEM, MDA-MB-231-*BCRP versus* MDA-MB-231-*pcDNA*, HCT116 *p53*$^{-/-}$ *versus* HCT116 *p53*$^{+/+}$ and U87.MGΔEGFR *versus* U87.MG; [b]The selectivity index: ratio of IC$_{50}$ in AML12 *versus* IC$_{50}$ in HepG2 cells [36, 37]. Tested samples were the methanol extract from leaves (BTL), ethyl acetate fraction from BTL (BTLa), and residue obtained after partition of BTL with ethyl acetate (BTLb) of *Bauhinia thonningii*. In bold: significant cytotoxic effect [61, 63]

Table 2 Cytotoxicity of the phytoconstituents isolated from the leaves of *Bauhinia thonningii* against the studied cancer cells

Cell lines	Samples, IC_{50} (µM), degrees of resistance[a] or selectivity index[b] (in bracket)									
	1	2	3	4	5	6	7	8	9	10
CCRF-CEM	14.23±0.94	12.02±1.25	17.85±1.67	27.32±3.12	**8.73±0.62**	**9.12±0.59**	**6.61±0.41**	**3.03±0.37**	>50	44.28±3.91
CEM/ADR5000	10.28±0.44	**9.11±0.18**	10.24±0.30	>50	**7.21±0.61**	**7.88±0.58**	**2.86±0.17**	**2.42±0.30**	>50	>50
Degree of resistance[a]	(0.72)	(0.76)	(0.57)	(>1.83)	(0.83)	(0.90)	(0.43)	(0.80)		(>1.13)
MDA-MB-231-pcDNA	11.28±1.04	**9.84±0.66**	11.02±0.58	42.28±3.29	**7.24±0.47**	**6.99±0.28**	**1.93±0.19**	**2.34±0.31**	>50	>50
MDA-MB-231-BCRP	16.98±2.05	14.29±1.12	13.19±1.48	>50	16.82±1.26	12.30±0.97	**8.15±0.73**	**8.26±0.66**	>50	>50
Degree of resistance	(1.51)	(1.45)	(1.20)	(>1.18)	(2.32)	(1.76)	(4.22)	(3.53)		
HCT116 $p53^{+/+}$	21.18±2.45	12.27±1.24	19.78±0.78	>50	17.93±1.26	21.84±2.11	19.50±2.05	**9.59±0.84**	>50	>50
HCT116 $p53^{-/-}$	10.77±1.11	**9.20±0.45**	17.23±0.83	>50	13.20±1.14	12.49±1.36	**9.71±0.76**	**3.41±0.35**	>50	>50
Degree of resistance	(0.51)	(0.75)	(0.87)		(0.73)	(0.57)	(0.50)	(0.36)		
U87MG	27.15±3.07	24.78±2.22	31.02±2.65	>50	23.65±1.77	19.03±2.01	19.27±1.62	**8.01±0.84**	>50	>50
U87MG.ΔEGFR	26.63±1.13	21.09±2.40	19.75±0.96	>50	31.09±1.85	33.54±2.79	18.01±2.21	15.38±0.64	>50	>50
Degree of resistance	(0.98)	(0.85)	(0.64)		(1.31)	(1.75)	(0.93)	(1.92)		
HepG2	23.46±0.59	19.55±1.44	23.57±3.23	>50	28.29±1.74	21.48±2.25	30.67±1.86	19.39±2.07	>50	>50
AML12	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
Selectivity index[b]	(>2.13)	(>2.56)	(>212)		(>1.77)	(>2.33)	(>1.63)	(>2.58)		

In bold: significant cytotoxic effect [61, 63]; Compounds: 6-C-methylquercetin-3, 4′-dimethyl ether (1); 6-C-methylquercetin-3, 7,3′-dimethyl ether (2); 6-C-methylquercetin 3,7,3′-trimethyl ether (3); quercetin (4); quercetin-3-O_L-rhamnopyranoside (5); quercetin-3-O-β-glucopyranoside (6); 6,8-C-dimethylkaempferol 3,7-dimethyl ether (7); 6,8-C-dimethylkaempferol-3-methyl ether (8) ursolic acid (9) and 3-O-β-$_D$-glucopyranoside of β-sitosterol (10); [a] The degree of resistance was determined as the ratio of the IC_{50} in the resistant divided by the IC_{50} in the sensitive cell lines; CEM/ADR5000 *versus* CCRF-CEM, MDA-MB-231-*BCRP versus* MDA-MB-231-*pcDNA*, HCT116 $p53^{-/-}$ *versus* HCT116 $p53^{+/+}$ and U87MG.ΔEGFR *versus* U87.MG; [b] The selectivity index: ratio of IC_{50} in AML12 *versus* IC_{50} in HepG2 cells [36, 37]

Matieta *et al. BMC Complementary Medicine and Therapies*   (2023) 23:341

Page 8 of 20

Table 3 Effect of BTL on hematological parameters of animals

Sexes	Studies animals, doses, and values of investigated parameters				
	Parameters	Doses of BTL and values of parameters			
		Control (0 mg/kg)	250 mg/kg	500 mg/kg	1000 mg/kg
Females	WBC (10^3/ml)	8.68 ± 1.79^a	7.96 ± 0.89^a	7.50 ± 1.62^a	7.60 ± 1.41^a
	RBC (10^6/mL)	7.92 ± 0.19^a	8.09 ± 0.27^a	8.34 ± 0.20^a	8.07 ± 0.24^a
	Hb (g/dL)	13.87 ± 0.33^a	13.48 ± 0.73^a	14.23 ± 0.26^a	14.50 ± 0.37^a
	HCT (%)	40.52 ± 1.47^a	41.65 ± 0.21^a	41.86 ± 0.66^{ab}	41.87 ± 1.47^{ab}
	PLT (10^3/mL)	600.83 ± 11.30^a	588.16 ± 16.57^a	599.66 ± 11.94^a	602.00 ± 14.13^a
	LYM (%)	58.85 ± 4.84^a	60.18 ± 0.59^a	54.00 ± 6.64^a	56.35 ± 3.17^a
	MID (%)	8.75 ± 0.73^a	8.00 ± 1.97^a	7.20 ± 1.13^a	8.05 ± 1.40^a
	GRAN%	31.82 ± 4.68^a	33.38 ± 0.82^a	34.12 ± 1.81^a	32.97 ± 5.98^a
Males	WBC (10^3/ml)	9.92 ± 0.47^a	9.30 ± 4.08^a	8.86 ± 4.10^a	10.50 ± 1.98^a
	RBC (10^6/mL)	8.44 ± 0.61^a	8.08 ± 0.41^a	8.33 ± 0.28^a	7.94 ± 0.70^a
	Hb (g/dL)	14.66 ± 0.68^a	13.85 ± 0.36^a	14.84 ± 0.44^a	13.47 ± 1.55^a
	HCT (%)	42.12 ± 1.91^a	40.15 ± 1.80^a	42.62 ± 2.10^a	40.53 ± 2.18^a
	PLT (10^3/mL)	667.75 ± 82.77^{ab}	568.75 ± 49.64^a	704.25 ± 98.58^b	632.00 ± 19.20^{ab}
	LYM (%)	53.37 ± 3.01^a	54.48 ± 3.70^a	54.77 ± 5.61^a	55.83 ± 1.65^a
	MID (%)	9.45 ± 0.50^a	9.55 ± 1.72^a	9.22 ± 0.98^a	10.95 ± 1.49^a
	GRAN%	32.53 ± 2.52^a	34.05 ± 2.18^a	32.11 ± 1.65^a	32.88 ± 3.05^a

Data are expressed as mean $\pm$ SD, $n = 4$. Values for a given group in a line followed by a different letter as a superscript are significantly different ($P < 0.05$). *RBC* red blood cells, *Hb* hemoglobin, *LYM* lymphocytes, *MID* mean corpuscular volume, *GRAN* granulocytes, *WBC* white blood cells, *PLT* platelets, *HCT* hematocrit

the nine tested cancer cell lines (Table 1). The obtained IC_{50} values varied from 18.13 μg/mL (against CCRF-CEM cells) to 40.84 μg/mL (against HCT116 *p53*$^{+/+}$ cells) for BTL, from 12.46 μg/mL (against U87MG cells) to 47.40 μg/mL (against HCT116 *p53*$^{-/-}$cells) for BTLa, and from 16.55 μg/mL (against U87MG cells) to 64.74 μg/mL (against MDA-MB-231-*BCRP* cells) for BTLb. The obtained IC_{50} values with doxorubicin varied 0.02 μM (against CCRF-CEM cells) to 122.96 μM (against CEM/ADR5000 cells) (Table 1). The purification of BTLa led to compounds 1, 2, 4, and 8 whereas that of BTLb led to compounds 3, 5, 6, and 7. The cytotoxicity of compounds was further determined in the nine cancer cell lines, as for the botanicals, and the results are summarized in Table 2. Compounds 1–3 and 5–8 had antiproliferative effects with the IC_{50} values below 50 μM against all the investigated cancer cell lines whilst compounds 4 and 10 were selectively active. No activity at up to 50 μM was detected with compound 9. The IC_{50} values below 10 μM were obtained with compounds 2, 5, 6, 7, and 8 toward 3, 3, 3, 5, and 7 of the 9 tested cancer cell lines, respectively (Table 2). The best cytotoxic effects with IC_{50} values below 5 μM were achieved with compounds 7 against CEM/ADR5000 leukemia cells (2.86 μM) and MDA-MB-231-*pcDNA* breast adenocarcinoma cells (1.93 μM) and as well as compound 8 against CCRF-CEM leukemia cells (3.03 μM), CEM/ADR5000 cells (2.42 μM), MDA-MB-231-*pcDNA* (2.34 μM), and

HCT116 *p53*$^{-/-}$ cells (3.41 μM) (Table 2). Amongst these most active compounds, compounds 2, 6, and 8 as well as the botanicals were more selective to normal AML12 hepatocytes compared to HepG2 hepatocarcinoma cells, with selective indexes above 2 (Tables 1 and 2). Regarding the best samples, normal sensitivity or hypersensitivity (collateral sensitivity) of CEM/ADR5000 cells *versus* CCRF-CEM cells was achieved *vis-à-vis* BTLa (D. R. of 0.98), compounds 2 (D. R. of 0.76), 5 (D. R. of 0.83), 6 (D. R. of 0.90), 7 (D. R. of 0.43), and 8 (D. R. of 0.80). This was also the case for MDA-MB-231-*BCRP* cells *versus* MDA-MB-231-*pcDNA* cells *vis-à-vis* BTL (D. R. of 1.14) BTL a (D. R. of 1.13) and compound 3 (D. R. of 1.20), HCT116 *p53*$^{-/-}$ cells *versus* HCT116 *p53*$^{+/+}$ cells *vis-à-vis* BTL (D. R. of 0.70), BTLa (D. R. of 1.08), BTLb (D. R. of 0.93), compounds 2 (D. R. of 0.75), 5 (D. R. of 0.73), 6 (D. R. of 0.57), 7 (D. R. of 0.50), and 8 (D. R. of 0.36), and U87.MG$\Delta EGFR$ cells *versus* U87.MG cells *vis-à-vis* BTL (D. R. of 1.07), compounds 2 (D. R. of 0.85), and 7 (D. R. of 0.93) (Table 2).

Cell cycle distribution and apoptosis

The modification of the life cycle in CCRF-CEM after the application of BTL, compound 8, and doxorubicin is shown in Fig. 2. Dose-dependent modifications of the various phases of the cell cycles can be observed because of the treatment with all studied samples. In effect, at higher 2×IC_{50}, BTL induces cell cycle arrest in the G0/

Matieta *et al. BMC Complementary Medicine and Therapies* (2023) 23:341

Page 9 of 20

Fig. 2 Effects of the crude extract (BTL) and compound 8 from the leaves of *Bauhinia thonningii*, and doxorubicin on the cycle distribution in CCRF-CEM cells after 24 h treatment. IC50 values 14.23 μg/mL for BTL, 3.03 μM for compound 8 and 0.02 μM for doxorubicin. Control cells were treated with DMSO to a final concentration of 0.1%. (**): values were significantly different to those of untreated control ($p < 0.05$); The propidium iodide (PI) staining was used for the cell cycle analysis by the flow cytometry; BTL, compound 8 and doxorubicin induced apoptosis in CCRF-CEM cells as shown with increase in cells in sub-G0/G1 phase. At higher concentration (2×IC50), BTL induces cell cycle arrest in G0/G1 phase; compound 8 induced cell cycle arrest in G2/M phase; doxorubicin induced cell cycle arrest in G2/M and S phases

G1 phase; compound 8 induces cell cycle arrest in the G2/M phase while doxorubicin induces cell cycle arrest in the G2/M and S phases. Furthermore, the number of cells in the sub-G0/G1 phase also increased significantly ($p < 0.05$) in a concentration-dependent manner upon treatments; within the concentrations ranges of $1/4 \times \mathrm{IC}_{50}$ and $2 \times \mathrm{IC}_{50}$, the number of cells in the sub-G0/G1 phase varied from 3.92 to 27.40% for BTL, 2.36 to 21.51% for compound 8, and from 3.28 to 12.05% for doxorubicin (Fig. 2). This is an indication that these samples induced apoptosis in CCRF-CEM cells. This was confirmed with annexin V/PI staining as summarized in Fig. 3. BTL, compound 8, and doxorubicin induced early apoptosis with high proportions of annexin V (+)/PI (-) cells, up to 64.2%, 67.3%, and 52.5% respectively, against 0.4% for non-treated cells.

Activation of caspases

The botanical BTL and the phytochemical 8 were used to treat CCRF-CEM cells at various concentrations for 6 h followed by the determination of caspase activity. The data are depicted in Fig. 4. The activity of caspases 3/7, 8, and 9 in CCRF-CEM cells upon treatments with BTL and compound 8 increased by 2.38-fold, 2.01-fold, and 2.15-fold as well as by 4.41-fold, 3.63-fold, and 4.22-fold, respectively. This clearly suggests the activation of these enzymes.

States of MMP and ROS

The state of MMP of CCRF-CEM cells upon application of BTL, compound 8, and valinomycin for 24 h followed by JC-1 staining is shown in Fig. 5. It can be noticed that the MMP in the cells was considerably altered. At $2 \times \mathrm{IC}_{50}$, only 1.23%, 23.0%, and 38.6% cells with intact

MMP were observed after the application of BTL, compound 8, and valinomycin, respectively. In comparison, up to 92.6% of cells with healthy MMP were recorded in untreated control under the same experimental condition. Concerning ROS levels, a significant dose-dependent increase ($p < 0.05$) of the production in CCRF-CEM cells was recorded upon treatment with BTL, compound 8, and H_2O_2 (Fig. 6). For instance, the ROS level in untreated cells was only 0.6% against 8.00%, 24.50% at $2 \times \mathrm{IC}_{50}$ in cells treated with BTL and compound 8, respectively, and 94.30% in cells treated with H_2O_2 at 50 μM.

Acute oral toxicity study

The botanical, BTL at dose 5000 mg/kg b. w. in acute administration did not cause deaths, signs of toxicity or mobility, somnolence, salivation, response to noise, stool appearance, etc. in the animals during the first 3 h after administration of the extract and during the 14 days of observation. No macroscopic or microscopic change was observed in organ tissues of animals given 5000 mg/kg b. w. of extract after 14 days of observation (data not shown).

Sub-chronic oral toxicity study

Effect of oral administration of BTL on the evolution of food consumption of rats and body weight

Figures 7 and 8 show the evolution of food consumption and body weight of the animals during the 28 days of sub-chronic administration of BTL. The repeated administration of different doses of the extract did not produce a significant difference in the food consumption of male and female rats compared to the control animals

Fig. 3 Effects of the crude extract (BTL) and compound 8 from the leaves of *Bauhinia thonningii*, and doxorubicin on apoptosis in CCRF-CEM cells after 24 h treatment. Q1-LL: viable cells with annexin V (-)/PI (-) stain; Q1-LR: early apoptotic cells with annexin (+)/PI (-) stain; Q1-UR and Q1-UL: late apoptotic cells or necrotic cells with annexin V (+)/PI (+) or annexin V (-)/PI (+) stains. IC_{50} values 14.23 μg/mL for BTL, 3.03 μM for compound 8, and 0.02 μM for doxorubicin. Control cells were treated with DMSO to a final concentration of 0.1%. The annexin V/propidium iodide (PI) staining combined with flow cytometry to detect the apoptosis; BTL, compound 8, and doxorubicin induced early apoptosis with a high proportion of annexin V (+)/PI (-) cells

(Fig. 7). However, Fig. 8 shows a progressive decrease in body weight in the animals given different doses of extract compared to the control animals. This decrease in body weight was inversely proportional to the dose. The animals of both sexes that received the highest doses of extract had the lowest body weight on day 28.

Effect of oral administration of BTL on relative organ weight

The effect of BTL on the relative organ weight of the animals after 28 days of administration is shown in Fig. 9. There were no significant changes in the liver, kidney, spleen, lungs, and heart weight in animals given different doses of extract compared to the control animals of both sexes.

Effect of oral administration of BTL on hematological parameters

Table 3 shows the effects of BTL on hematological parameters after 28 days of repeated oral administration. No significant ($p \geq 0.05$) changes in hematological parameters were observed in animals of both sexes at all doses of the extract when compared to the animals in the control group.

Effect of oral administration of BTL on kidney function markers of animals

The effect of BTL on markers of rat kidney function after 28 days of administration is shown in Table 4. These results show that except for serum creatinine at 1000 mg/kg dose, which was significantly increased, no significant

Fig. 4 Effects of the crude extract (BTL) and compound 8 from the leaves of *Bauhinia thonningii* on the activity of caspases in CCRF-CEM cells after 6 h treatment. IC_{50} values 14.23 µg/mL for BTL and 3.03 µM for compound 8. Control cells were treated with DMSO to a final concentration of 0.1%. The Caspase-Glo assay was used to detect the activity of Caspases; Caspase activity was expressed as percentage (%) compared to untreated cells. Results display mean values ± SD of three assays. BTL slightly induced the activation of caspases 3/7, 8, and 9; compound 8 induced higher activation of caspases 3/7, 8, and 9

variation ($p < 0.05$) was observed with the other parameters measured compared to the animals in the control group.

Effects of BTL on markers of the liver and cardiovascular function

The effect of sub-acute oral administration of BTL on biochemical markers of the liver and cardiovascular function is presented in Table 5. Analysis of the liver function markers revealed a significant ($p < 0.05$) decrease in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities at 250 and 500 mg/kg in both sexes compared to those in the control group. Further analysis of cardiovascular markers revealed a significant ($p < 0.05$) increase in LDL cholesterol levels at 500 and 1000 mg/kg in females compared to the control group. However, in males, a significant ($p < 0.05$) increase in total and high-density lipoprotein HDL cholesterol levels at doses 500 and 1000 mg/Kg b. w. compared to those in the control group was observed. Similarly, sub-acute administration of methanol extract of BTL resulted in a significant decrease in LDL-cholesterol level at 250 mg/kg b. w. in males compared to the control group.

Histological sections of the liver and kidneys

Histopathological analysis of the liver and kidneys of both males and females revealed no abnormalities at all

doses of BTL used in this test compared to the control animals (Fig. 10).

Discussion

Cancer chemotherapy is seriously hampered by the rapid development of resistance to cytotoxic drugs. A good strategy for the new anticancer drug discovery should integrate the models of drug resistant cells [33, 39]. In the present study, the drug-resistant cancer cell lines included the P-gp-overexpressing CEM/ADR 5000 cells, the breast cancer resistance protein-expressing MDA-MB 231-*BCRP* cell lines, U87MG.*ΔEGFR* cells with mutation-activated *EGFR* gene (*ΔEGFR*) as well as the *p53* knockout HCT116*p53$^{-/-}$* cells [56–59]. To appreciate the importance of the studied samples as alternatives to combat cancer drug resistance, the drug sensitive counterparts of the above-mentioned resistant cells were used simultaneously. Cytotoxic medicines with the ability to tackle cancer drug resistance should show collateral or normal sensitivities of resistant cancer cells towards them [36, 37, 60, 61]. Moreover, efficient cytotoxic drugs should display IC_{50} values below 20 µg/mL for botanicals [62] or below 10 µM for phytochemicals [63]. Interestingly, the IC_{50} values below 20 µg/mL were recorded in the present work with BTL, BTLb, and BTLa on 1, 2, and 6 of the 9 tested cancer cell lines, respectively (Table 1). The IC_{50} values below 10 µM were obtained with compounds 2, 5, 6, 7, and 8 in at least 6/9 tested cancer cell

Fig. 5 Effects of the crude extract (BTL) and compound 8 from the leaves of *Bauhinia thonningii*, valinomycin on the mitochondrial membrane potential (MMP) of CCRF-CEM cells after 24 h treatment. IC50 values 14.23 μg/mL for BTL and 3.03 μM for compound 8. Control cells were treated with DMSO to a final concentration of 0.1%. The 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) staining combined to flow cytometry was used to analyze the MMP. Q1 represents cells with undamaged MMP, Q2 represents cells with MMP loss whereas Q3-Q4 represents cells with disrupted MMP. BTL, compound 8 or valinomycin strongly altered the integrity of the MMP

lines (Table 2). This is a clear indication that these samples are potential cytotoxic agents. Besides, collateral or normal sensitivity of at least one model of the drug resistant cell line compared to their drug sensitive congener was reported with BTL, BTL a, and BTLb, compounds 2, 5, 6, 7, and 8 (Table 2). This also suggests that these samples could be useful in the fight against refractory cancers. To the best of our knowledge, the cytotoxicity of botanicals from *Bauhinia thonningii* as well as some of its phytoconstituents: 6-C-methylquercetin-3, 4'-dimethyl ether (1), 6-C-methylquercetin-3,7-dimethyl ether (2), 6-C-methylquercetin 3,7,3'-trimethyl ether (3), quercetin-3-*O*-L-rhamnopyranoside (5), quercetin-3-*O*-β-glucopyranoside (6), 6,8-C-dimethylkaempferol 3,7-dimethyl ether (7), 6,8-C-dimethylkaempferol-3-methyl ether (8) in such a broad panel of cancer cell lines including MDR phenotypes has been reported for the first time. However, the cytotoxicity of quercetin (4) was shown in CCRF-CEM cells and CEM/ADR5000 cells, with the IC$_{50}$ values of 25 μM and 101 μM, respectively [64]. This corroborates the data obtained in the present study as compound 4 had a closer IC$_{50}$ value of 27 μM in CCRF-CEM cells and a value above 50 μM in CEM7ADR5000 cells. Furthermore, the data obtained with *β*-sitosterol-3-*O*-β-D-glucopyranoside (10) corroborate the previous studies as this compound was found not active in

Matieta *et al. BMC Complementary Medicine and Therapies* (2023) 23:341

Page 13 of 20

Fig. 6 Effects of the crude extract (BTL) and compound 8 from the leaves of *Bauhinia thonningii* and of hydrogen peroxide (H_2O_2) on the reactive oxygen species (ROS) production in CCRF-CEM cells upon 24 h treatment. IC_{50} values 14.23 µg/mL for BTL and 3.03 µM for compound 8. Control cells were treated with DMSO to a final concentration of 0.1%. The ROS level was determined by the combined 2′,7′-dichlorodihydrofluorescein diacetate staining and flow cytometry; (**): values are significantly different to those of untreated control ($p < 0.05$). Results display mean values ± SD of three assays. BTL slightly enhanced ROS production; compound 8 enhanced higher ROS production


Fig. 7 Effect of sub-chronic administration of BTL on food consumption of rats. Data are expressed as mean ± SD, $n = 4$. No significant difference was observed ($p < 0.05$)

Fig. 8 Effect of sub-chronic administration of BTL leaves on body weight of rats. Data are expressed as mean ± SD, $n = 4$. Values for a given group in a line followed by different symbols are significantly different ($p < 0.05$)


Fig. 9 Effect of BTL on the relative organ weight of animals after 28 days of oral administration. Data are expressed as mean ± SD, $n = 4$. Values for a given group in a line followed by different symbols were significantly different ($p < 0.05$)

the cancer cell lines tested in the current work with IC_{50} values above 100 μM [65]. In the present study, ursolic acid (9) showed a low cytotoxic effect in a single cancer cell line, CCRF-CEM with an IC_{50} value of 44.28 μM.

This also corroborates other reports on this compound. For instance, Shyu reported an IC_{50} value of 75 μM for compound 9 in human hepatocellular carcinoma HuH7 cells [66]; the IC_{50} value of 7.1 μg/mL (or 15.57 μM) was

Matieta *et al. BMC Complementary Medicine and Therapies*   (2023) 23:341

Page 15 of 20

Table 4 Effects of BTL on kidney function markers of animals

Sexes	Studies animals, doses, and values of investigated parameters				
	Parameters	Doses of BTL and values of parameters			
		Control (0 mg/kg)	250 mg/kg	500 mg/kg	1000 mg/kg
Females	S-Crea (mg/dL)	0.84 ± 0.02^a	0.83 ± 0.02^a	0.85 ± 0.01^a	0.97 ± 0.03^b
	S-Urea (mg/dL)	4.30 ± 0.42^a	4.11 ± 0.37^a	4.36 ± 0.33^a	4.24 ± 0.40^a
	U-Crea (mg/dL)	212.03 ± 19.72^{ab}	180.49 ± 14.40^a	226.77 ± 23.32^b	224.01 ± 22.79^b
	U-Proteins (g/dL)	$0.04.03 \pm 0.00^a$	0.03 ± 0.00^a	0.04 ± 0.00^a	0.04 ± 0.00^a
	U-Urea (mg/dL)	482.13 ± 30.37^a	465.41 ± 30.93^a	493.03 ± 26.84^a	461.55 ± 21.38^a
Males	S-Crea (mg/dL)	0.83 ± 0.02^a	0.80 ± 0.05^a	0.80 ± 0.07^a	0.79 ± 0.08^a
	S-Urea (mg/dL)	3.62 ± 0.43^{ab}	3.97 ± 0.13^b	3.22 ± 0.45^a	3.85 ± 0.35^{ab}
	U-Crea (mg/dL)	257.10 ± 37.69^a	246.09 ± 28.48^a	255.03 ± 27.55^a	248.12 ± 7.66^a
	U-Proteins (g/dL)	0.04 ± 0.00^{ab}	0.05 ± 0.00^{ab}	0.04 ± 0.00^a	0.06 ± 0.00^b
	U-Urea (mg/dL)	451.08 ± 78.88^a	501.25 ± 46.65^a	439.74 ± 25.76^a	496.46 ± 74.50^a

Data are expressed as mean $\pm$ SD, $n = 4$. Values for a given group in a column followed by a different letter as a superscript are significantly different ($p < 0.05$). *S-Crea* serum creatinine, *U-Crea* urine creatinine, *S-Urea* serum urea, *U-Urea* urine urea, *U-Proteins* urine proteins

Table 5 Effect of BTL on the liver and cardiovascular markers of animals

Sexes	Studies animals, doses, and values of investigated parameters				
	Parameters	Doses of BTL and values of parameters			
		Control (0 mg/kg)	250 mg/kg	500 mg/kg	1000 mg/kg
Females	Proteins (g/dL)	5.12 ± 0.30^a	4.87 ± 0.16^a	4.79 ± 0.41^a	4.97 ± 0.54^a
	ALT (U/l)	40.46 ± 1.36^b	33.46 ± 2.02^a	36.36 ± 1.14^a	46.37 ± 5.44^b
	AST (U/l)	80.90 ± 1.43^a	75.36 ± 2.60^a	74.63 ± 1.60^a	83.93 ± 5.80^b
	TAG (mg/dL)	41.66 ± 2.9^{ab}	47.96 ± 3.33^b	35.55 ± 4.60^a	45.92 ± 3.60^b
	Cholesterol(mg/dL)	84.00 ± 7.38^a	80.75 ± 3.27^a	72.75 ± 6.76^a	85.62 ± 6.35^a
	LDL (mg/dL)	7.04 ± 0.87^a	6.65 ± 0.39^a	7.73 ± 0.22^b	8.31 ± 0.20^c
	HDL (mg/dL)	68.62 ± 6.61^{ab}	64.50 ± 3.63^{ab}	57.90 ± 7.02^a	68.13 ± 2.52^b
Males	Proteins (g/dL)	6.53 ± 0.51^a	6.27 ± 0.36^a	6.23 ± 0.44^a	6.77 ± 0.34^a
	ALT (U/l)	45.50 ± 1.06^b	39.37 ± 0.57^a	38.71 ± 1.95^a	49.87 ± 5.10^b
	AST (U/l)	130.37 ± 7.30^b	78.53 ± 8.57^a	80.28 ± 7.07^a	134.74 ± 7.26^b
	TG (mg/dL)	66.48 ± 5.32^b	58.70 ± 8.79^{ab}	50.00 ± 8.25^a	71.85 ± 8.99^b
	Cholesterol (mg/dL)	86.58 ± 1.70^a	79.50 ± 5.91^a	95.50 ± 4.73^b	97.37 ± 2.49^b
	LDL (mg/dL)	19.45 ± 0.81^b	15.41 ± 0.42^a	18.13 ± 1.16^b	20.75 ± 0.91^b
	HDL (mg/dL)	53.75 ± 1.84^a	52.35 ± 3.59^a	66.63 ± 5.51^b	62.25 ± 2.39^b

Data are expressed as mean $\pm$ SD, $n = 4$. Values for a given group in a Line followed by a different letter as a superscript were significantly different ($p < 0.05$). *ALT* alanine transaminase, *AST* aspartate transaminase, *HDL* high-density lipoprotein, *LDL* low-density lipoprotein, *TG* triglycerides

also reported with compound 9 against MCF-7 cells [67]. Regarding the structure–activity relationship, the two isolated terpenoids (9 and 10) appear to have much lower cytotoxic effects than the flavonol derivatives 1 to 8 (Table 2). Within the flavonol derivatives, the types as well as the number of substituents in the flavonol moiety seem to influence the cytotoxic effects. Compound 4 with the lowest number of substituents (two hydroxyl groups) had the lowest spectrum of cytotoxic activity with IC_{50} values recorded in only two of the 9 tested cancer cell lines (Table 2). Compounds 1 and 3 are isomers with some differences found in the positions of *O*-methyl and hydroxyl groups in positions C7 and C4'. This resulted in a slight but not significant variation of the activity of the two compounds (Fig. 1; Table 2). The difference between compounds 5 and 6 is the presence of rhamnosyl substituent in position C3 (5) instead of glucosyl substituent (6). However, this change in the nature of the sugar did not

Fig. 10 Histopathological analysis of the kidneys and the liver of males and females. Kidney: G = Glomerulus, Eu = Urinary space, Tcd = Distal bypass tubule, Tcp = Proximal bypass tubule. Liver: Vp = Portal vein, He = Hepatocyte, Cb = Bile canaliculus, Ah = Hepatic artery

seem to influence the cytotoxic effects of the two compounds as they had rather close inhibitory effects in all tested cancer cell lines (Fig. 1; Table 2). The difference between compounds 7 and 8 is the presence of *O*-methyl substituent in position C7 (7) instead of hydroxyl substituent (8) (Fig. 1). This substitution of *O*-methyl for hydroxyl seems to significantly increase the degree of the cytotoxicity of compound 8 (Table 2). IC$_{50}$ values below 10 µM were obtained in 7/9 cancer cell lines with compound 8 and in only 5/9 for compound 7 (Table 2).

Apoptosis has been identified as one of the likely modes of action of several natural products including flavonoids [36, 61]. In this study, BTL and flavonoid 8 induced apoptosis in CCRF-CEM cells via caspase activation, MMP alteration, and increased ROS production. Though the mode of induction of apoptosis in CCRF-CEM cells by compound 8 (a kaempferol derivative) has not been reported yet, that of kaempferol is well-known in several cancer cell lines [68]. The results obtained in this work are therefore in conformity with the data on the mode of action of flavonols.

The toxicological profile of a substance is useful in the assessment of risks to humans [8, 69, 70]. However, adverse changes in animals have a strong predictive value for human toxicity especially as an active extract can be toxic to the host. It was important to assess the

safety level of BTL in view of the promising cytotoxic data reported in this study. The acute toxicity evaluation of BTL revealed no deaths and no toxic signs in animals given an extract at a dose of 5000 mg/kg b. w. This indicates a high tolerance of rats to the extract. In accordance with this result, the LD$_{50}$ of the BTL is above 5000 mg/kg b. w., which means that according to the Hodge and Sterner toxicity scale, this extract can be classified as being of low or no toxicity [71]. This result is in close agreement with the work of Olela et al. [72] who obtained an LD$_{50}$ > 2000 mg/kg b. w. in the acute oral administration (in mice) of the aqueous and methanol extracts of *Bauhinia thonningii* bark harvested in Kenya. The sub-chronic administration of BTL at different doses for 28 days did not lead to any variation ($p > 0.05$) in food consumption. However, the decrease in weight growth in animals is not a sign of toxicity in view of the overall results observed as it is traditionally used in West Cameroon for its anti-obesity properties. This extract could therefore be beneficial for people suffering from obesity. According to Raji et al. [73], a plant extract with anti-obesity properties causes a decrease in the body weight of animals in toxicological studies.

Hematopoiesis is a vital process for life and can be affected by both conventional and herbal drugs. The assessment of hematological parameters in animal

Matieta *et al. BMC Complementary Medicine and Therapies* (2023) 23:341

Page 17 of 20

models provides information on the benefits or toxic manifestations of herbal extracts in the blood [74]. The results of the hematological evaluation in rats treated with BTL did not show significant changes in hematological parameters. This indicates that the different doses of the extract used do not affect hematopoiesis. The significant decrease ($p < 0.05$) in ALT and AST activity at doses of 250 and 500 mg/kg in animals of both sexes reflects the protective effect of the extract at these doses on the liver. Indeed, the botanicals with beneficial health effects act by reinforcing the selective permeability of the cell membranes. This led to a decrease in the level of enzymes and serum proteins [75]. The decrease in serum activities of its enzymes is a benefit to the liver and may reflect the protective effect of BTL on the liver. This non-hepatotoxic effect of BTL is confirmed by macroscopic and histopathological analysis of the liver that showed no lesions at all treatment doses in male and female animals and no significant variation in the relative liver weight. The kidney similarly to the liver is a key organ in toxicological assessment due to its marginal involvement in blood purification and excretion of waste products in the body. Its proper functioning can be assessed through certain parameters such as urinary proteins, urea, and creatinine. An increase in the urinary concentration of the latter will reveal the alteration of renal function [76]. The analysis of the results revealed no significant variation in urinary protein, urea and creatinine levels in rats of both sexes given different doses of BTL. Similarly, no pathological changes were observed in the histology of the kidneys of animals of both sexes. This indicates that BTL was not nephrotoxic at the doses used in this test. The administration of the plant extract in rats can also affect their lipid profile which is a set of parameters such as LDL-cholesterol, total cholesterol, and triglycerides that are mainly involved in the risk factors of cardiovascular diseases [77]. Based on the analysis of the lipid profile results, there was a significant decrease in LDL cholesterol levels at the dose of 250 mg/kg b. w. The LDL-cholesterol is the variant mostly occurring in pathological conditions, and its reduction as observed in this study reduces the risk of developing cardiovascular diseases.

Conclusion

In the present work, the cytotoxicity of the methanol extract from the leaves of *Bauhinia thonningii* (BTL) as well as fractions (BTLa and BTLb) and their isolated phytoconstituents was evidenced on a panel of human cancer cell lines including MDR phenotypes. The isolated phytochemicals were 6-C-methylquercetin-3,4'-dimethyl ether (1), 6-C-methylquercetin-3,7-dimethyl ether (2), 6-C-methylquercetin 3,7,3'-trimethyl ether (3),

quercetin (4), quercetin-3-O-$_L$-rhamnopyranoside (5), quercetin-3-O-β-glucopyranoside (6), 6,8-C-dimethylkaempferol 3,7-dimethyl ether (7), 6,8-C-dimethyl-kaempferol-3-methyl ether (8), ursolic acid (9), and 3-O-β-$_D$-glucopyranoside of β-sitosterol (10). The botanicals (BTL, BTL a, and BTLb) as well as compounds 2, 5, 6, 7, and 8 had promising cytotoxic effects. BTL and compound 8 induced apoptotic cell death in CCRF-CEM cells through caspase activation, alteration of MMP, and increased ROS production. BTL did not cause any adverse effects in rats after a single administration at 5000 mg/kg as well as the repeated dose of 250 mg/kg b. w. *Bauhinia thonningii* and its constituents are sources of cytotoxic drugs and deserve more in-depth studies to develop novel antiproliferative phytomedicine to fight cancer including resistant phenotypes.

Abbreviations

1	6-C-methylquercetin-3, 4'-dimethyl ether
2	6-C-methylquercetin-3,7-dimethyl ether
3	6-C-methylquercetin 3,7,3'-trimethyl ether
4	Quercetin
5	Quercetin-3-O-$_L$-rhamnopyranoside
6	Quercetin-3-O-β-glucopyranoside
7	6,8-C-dimethylkaempferol 3,7-dimethyl ether
8	6,8-C-dimethylkaempferol-3-methyl ether
9	Ursolic acid
10	β-Sitosterol-3-O-β-$_D$-glucopyranoside
ALT	Alanine transaminase
AST	Aspartate transaminase
BCRP	Breast cancer resistance protein;
b. w.	Body weight
CC	Column chromatography
DMSO	Dimethyl sulfoxide
D. R.	Degree of resistance
EDTA	Ethylenediaminetetraacetic acid
EGFR	Epidermal growth factor receptor
EtOAc	Ethyl acetate
FITC	Fluorescein isothiocynate
H_2DCFH-DA	2',7'-Dichlorodihydrofluorescein diacetate
HDL	High-density lipoprotein
HNC	Cameroon National Herbarium
IC$_{50}$	Inhibitory concentration 50
JC-1	5,5',6,6'-Tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide
m. p.	Melting point
m/z	Molecular weight
LDL	Low density lipoprotein
MDR	Multidrug-resistant
MMP	Mitochondrial membrane potential
P-gp	P-glycoprotein
PI	Propidium iodide
BTL	Methanol extract from the leaves of *Bauhinia thonningii*
BTL a and BTLb	Ethyl acetate and residual fractions from BTL
ROS	Reactive oxygen species
RRA	Resazurin reduction assay
SD	Standard deviation
S.I.	Selectivity index
sub-frs	Sub-fractions
TG	Triglycerides
WHO	World Health Organization

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12906-023-04172-9.

Additional file 1: Figure S1-Figure S24.

Authors' contributions

VYM: Investigation, writing-original draft.
ATM: Methodology, investigation, writing-original draft, conceptualization.
GRSN and SBT: Investigation, data analysis.
GTK, PN, and IC: Data analysis.
AML: Conceptualization.
TE: Conceptualization, funding, review & editing, validation.
VK: Conceptualization, Funding, review, editing, validation, supervision.
All authors have read and agreed to the published version of the manuscript.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Declarations

Ethics approval and consent to participate

The experimental protocols used for this study were approved by the Institutional Ethical Committee of the University of Dschang (Cameroon) and were designed in concordance with the internationally accepted standard ethical guidelines for laboratory animals use and care as described in the guidelines of the European Union Institutional Ethics Committee on Animal Care (Council EEC 86/609/EEC of the 24th November 1986). All sections of this report adhere to the ARRIVE Guidelines for reporting animal research [78]. The Research Committee of PhD Projects Evaluation of the Faculty of Science (University of Dschang) approved the collection of *Bauhinia thonningii* (Schumach.) Milne-Redh. (Fabaceae). The collection of the studied plant complied with relevant institutional, national, and international guidelines and legislation. The plant was identified and authenticated by Mr. NANA Victor as *Bauhinia thonningii* (Schumach.) Milne-Redh. (Fabaceae) in comparison to the specimen of the herbarium recorded under voucher number 33258/HNC.

Consent for publication

Not applicable.

Competing interests

VK is a Senior Editor of BMC Complementary Medicine and Therapy; ATM is an Associate Editor of BMC Complementary Medicine and Therapy. The remaining authors declare that they have no competing interests.

Author details

[1]Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon. [2]Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, University of Mainz, Staudinger Weg 5, 55128 Mainz, Germany. [3]Department of Chemistry, Faculty of Science, University of Maroua, Maroua, Cameroon. [4]Department of Chemistry, Faculty of Science, Eskişehir Technical University, Eskisehir, Turkey.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
2. Ngwa W, Addai BW, Adewole I, Ainsworth V, Alaro J, Alatise OI, Ali Z, Anderson BO, Anorlu R, Avery S, et al. Cancer in sub-Saharan Africa: a lancet oncology commission. Lancet Oncol. 2022;23(6):e251–312.
3. Ochwang'i DO, Kimwele CN, Oduma JA, Gathumbi PK, Mbaria JM, Kiama SG. Medicinal plants used in treatment and management of cancer in Kakamega County. Kenya J Ethnopharmacol. 2014;151(3):1040–55.
4. Kuete V, Efferth T. Pharmacogenomics of Cameroonian traditional herbal medicine for cancer therapy. J Ethnopharmacol. 2011;137(1):752–66.
5. Kuete V, Tangmouo JG, Penlap Beng V, Ngounou FN, Lontsi D. Antimicrobial activity of the methanolic extract from the stem bark of *Tridesmostemon omphalocarpoides* (Sapotaceae). J Ethnopharmacol. 2006;104(1–2):5–11.
6. Kuete V. Medicinal spices and vegetables from Africa: therapeutic potential against metabolic, inflammatory, infectious and systemic diseases. London: Academic Press; 2017.
7. Ngameni B, Kuete V, Simo IK, Mbaveng AT, Awoussong PK, Patnam R, Roy R, Ngadjui BT. Antibacterial and antifungal activities of the crude extract and compounds from *Dorstenia turbinata* (Moraceae). S Afr J Bot. 2009;75(2):256–61.
8. Mbaveng AT, Zhao Q, Kuete V. 20 - Harmful and protective effects of phenolic compounds from african medicinal plants. In: Toxicological Survey of African Medicinal Plants. edn. Edited by Kuete V. Oxford: Elsevier; 2014:577–609.
9. Tchinda CF, Voukeng KI, Beng VP, Kuete V. Antibacterial activities of the methanol extracts of *Albizia adianthifolia, Alchornea laxiflora, Laportea ovalifolia* and three other Cameroonian plants against multi-drug resistant Gram-negative bacteria. Saudi J Biol Sci. 2016;24:950–5.
10. Voukeng IK, Beng VP, Kuete V. Antibacterial activity of six medicinal Cameroonian plants against Gram-positive and Gram-negative multidrug resistant phenotypes. BMC Complement Altern Med. 2016;16(1):388.
11. Kuete V. Toxicological survey of African medicinal plants. Oxford: Elsevier; 2014.
12. Emmanuel HM, Gusau HL, Gidado LM, Ali B, Ugwah-Oguejiofor CJ, Yahaya A. Comparative studies on phytochemical and antioxidant activities of *Tapinanthus globiferus* and its host plant *Bauhinia thonningii* (A. Rich) (Schum). Adv Pharm J. 2017; 2(5):179–184.
13. Nouemsi GRS, Jouda JB, Leutcha PB, Matieta VY, Tsague Tankeu VF, Ngnouzouba Kuete JR, Çelik İ, Kuete V, Sewald N, Lannang AM. A new flavonol derivative and other compounds from the leaves of *Bauhinia thonningii* Schum with activity against multidrug-resistant bacteria. Nat Prod Res. 2022;37(16):2653–61.
14. Cordell G, Beecher C, Pezzut J. Can ethnopharmacology contribute to development of new anti-cancer? J Ethnopharmacol. 1991;32(1–2):117–33.
15. Popoca J, Aguilar A, Alonso D, Villarreal M. Cytotoxic activity of selected plants used as antitumorals in Mexican traditional medicine. J Ethnopharmacol. 1998;59(3):173–7.
16. Abdelwahab SI, Taha MM, Abdulla MA, Nordin N, Hadi AH, Mohan S, Jayapalan JJ, Hashim OH. Gastroprotective mechanism of *Bauhinia thonningii* Schum. J Ethnopharmacol. 2013;148(1):277–86.
17. Molander M, Nielsen L, Søgaard S, Staerk D, Rønsted N, Diallo D, Chifundera KZ, van Staden J, Jäger AK. Hyaluronidase, phospholipase A2 and protease inhibitory activity of plants used in traditional treatment of snakebite-induced tissue necrosis in Mali, DR Congo and South Africa. J Ethnopharmacol. 2014;157:171–80.
18. Kudi AC, Umoh JU, Eduvie LO, Gefu J. Screening of some Nigerian medicinal plants for antibacterial activity. J Ethnopharmacol. 1999;67(2):225–8.
19. Houphouët-Boigny F. Hypoglycemic and antihyperglycemic activities of *Bauhinia thonningii* (caesalpiniaceae) fruit in rat wistar. Indian J Res Pharm Biotechnol. 2018;6(1):25–9.
20. Ojezele MO, Abatan MO, Ohaju-Obodo JO. Hypoglycaemic and secondary complication ameliorating effects of solvent fractions of *Bauhinia Thonningii* in experimental diabetic rats. East Afr Med J. 2018;95(3):1323–30.
21. Kudi AC, Myint SH. Antiviral activity of some Nigerian medicinal plant extracts. J Ethnopharmacol. 1999;68(1–3):289–94.

Matieta *et al. BMC Complementary Medicine and Therapies*   (2023) 23:341

Page 19 of 20

22. Dieng SIM, FalL AD, Diatta-Badji K, Sarr A, Sene M, Mbaye A, Diatta W, Bassene E. Evaluation of the antioxidant activity of hydro-ethanolic leaf and bark extracts of *Piliostigma thonningii* Schumach. Int J Biol Chem Sci. 2017;11(2):768–76.

23. Kuete V, Wiench B, Alsaid MS, Alyahya MA, Fankam AG, Shahat AA, Efferth T. Cytotoxicity, mode of action and antibacterial activities of selected Saudi Arabian medicinal plants. BMC Complement Altern Med. 2013;13:354.

24. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, et al. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol. 2003;64(2):382–94.

25. Gillet J, Efferth T, Steinbach D, Hamels J, de Longueville F, Bertholet V, Remacle J. Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res. 2004;64(24):8987–93.

26. Kimmig A, Gekeler V, Neumann M, Frese G, Handgretinger R, Kardos G, Diddens H, Niethammer D. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res. 1990;50(21):6793–9.

27. Kuete V, Nkuete AHL, Mbaveng AT, Wiench B, Wabo HK, Tane P, Efferth T. Cytotoxicity and modes of action of 4'-hydroxy-2',6'-dimethoxychalcone and other flavonoids toward drug-sensitive and multidrug-resistant cancer cell lines. Phytomedicine. 2014;21(12):1651–7.

28. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A. 1998;95(10):5724–9.

29. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282(5393):1497–501.

30. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;95(26):15665–70.

31. Kuete V, Sandjo LP, Djeussi DE, Zeino M, Kwamou GM, Ngadjui B, Efferth T. Cytotoxic flavonoids and isoflavonoids from *Erythrina sigmoidea* towards multi-factorial drug resistant cancer cells. Invest New Drugs. 2014;32:1053–62.

32. Kuete V, Mbaveng AT, Sandjo LP, Zeino M, Efferth T. Cytotoxicity and mode of action of a naturally occurring naphthoquinone, 2-acetyl-7-methoxynaphtho[2,3-b]furan-4,9-quinone towards multi-factorial drug-resistant cancer cells. Phytomedicine. 2017;33:62–8.

33. Mbaveng AT, Bitchagno GTM, Kuete V, Tane P, Efferth T. Cytotoxicity of ungeremine towards multi-factorial drug resistant cancer cells and induction of apoptosis, ferroptosis, necroptosis and autophagy. Phytomedicine. 2019;60: 152832.

34. O'Brien J, Wilson I, Orton T, Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem. 2000;267(17):5421–6.

35. Kuete V, Ngameni B, Wiench B, Krusche B, Horwedel C, Ngadjui BT, Efferth T. Cytotoxicity and mode of action of four naturally occuring flavonoids from the genus *Dorstenia*: gancaonin Q, 4-hydroxylonchocarpin, 6-prenylapigenin, and 6,8-diprenyleriodictyol. Planta Med. 2011;77(18):1984–9.

36. Mbaveng AT, Kuete V, Efferth T. Potential of Central, Eastern and Western Africa medicinal plants for cancer therapy: spotlight on resistant cells and molecular targets. Front Pharmacol. 2017;8:343.

37. Efferth T, Saeed MEM, Kadioglu O, Seo EJ, Shirooie S, Mbaveng AT, Nabavi SM, Kuete V. Collateral sensitivity of natural products in drug-resistant cancer cells. Biotechnol Adv. 2020;38: 107342.

38. Mbaveng AT, Manekeng HT, Nguenang GS, Dzotam JK, Kuete V, Efferth T. Cytotoxicity of 18 Cameroonian medicinal plants against drug sensitive and multi-factorial drug resistant cancer cells. J Ethnopharmacol. 2018;222:21–33.

39. Mbaveng AT, Fotso GW, Ngnintedo D, Kuete V, Ngadjui BT, Keumedjio F, Andrae-Marobela K, Efferth T. Cytotoxicity of epunctanone and four other phytochemicals isolated from the medicinal plants *Garcinia epunctata* and *Ptycholobium contortum* towards multi-factorial drug resistant cancer cells. Phytomedicine. 2018;48:112–9.

40. Adem FA, Kuete V, Mbaveng AT, Heydenreich M, Ndakala A, Irungu B, Efferth T, Yenesew A. Cytotoxic benzylbenzofuran derivatives from *Dorstenia kameruniana*. Fitoterapia. 2018;128:26–30.

41. Kuete V, Dzotam JK, Voukeng IK, Fankam AG, Efferth T. Cytotoxicity of methanol extracts of *Annona muricata*, *Passiflora edulis* and nine other Cameroonian medicinal plants towards multi-factorial drug-resistant cancer cell lines. Springerplus. 2016; 27;5(1):1666.

42. Mbaveng AT, Chi GF, Nguenang GS, Abdelfatah S, Tchangna Sop RV, Ngadjui BT, Kuete V, Efferth T. Cytotoxicity of a naturally occuring spirostanol saponin, progenin III, towards a broad range of cancer cell lines by induction of apoptosis, autophagy and necroptosis. Chem Biol Interact. 2020;326: 109141.

43. Mbaveng AT, Noulala CGT, Samba ARM, Tankeo SB, Abdelfatah S, Fotso GW, Happi EN, Ngadjui BT, Beng VP, Kuete V, et al. The alkaloid, soyauxinium chloride, displays remarkable cytotoxic effects towards a panel of cancer cells, inducing apoptosis, ferroptosis and necroptosis. Chem Biol Interact. 2021;333: 109334.

44. Mbaveng AT, Ndontsa BL, Kuete V, Nguekeu YMM, Celik I, Mbouangouere R, Tane P, Efferth T. A naturally occuring triterpene saponin ardisiacrispin B displayed cytotoxic effects in multi-factorial drug resistant cancer cells via ferroptotic and apoptotic cell death. Phytomedicine. 2018;43:78–85.

45. Kuete V, Fankam AG, Wiench B, Efferth T. Cytotoxicity and modes of action of the methanol extracts of six Cameroonian medicinal plants against multidrug-mesistant tumor cells. Evid Based Complement Alternat Med. 2013;2013: 285903.

46. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol. 1983;130(4):1910–7.

47. Cossarizza A, Ferraresi R, Troiano L, Roat E, Gibellini L, Bertoncelli L, Nasi M, Pinti M. Simultaneous analysis of reactive oxygen species and reduced glutathione content in living cells by polychromatic flow cytometry. Nat Protoc. 2009;4(12):1790–7.

48. OECD: Organization for Economic Cooperation and Development (OECD) Guidelines for the Testing of Chemicals Acute Oral Toxicity–Up-And-Down Procedure (UDP); 2008a.

49. Bonsou IN, Mbaveng AT, Nguenang GS, Chi GF, Kuete V, Efferth T: Cytotoxicity, acute and sub-chronic toxicities of the fruit extract of *Tetrapleura tetraptera* (Schumm. & Thonn.) Taub. (Fabaceae). BMC Complement Med Ther. 2022; 22(1):178.

50. OECD: Organization for Economic Cooperation and Development Guidelines for the Testing of Chemicals/Draft Updated Test Guideline : Repeated Dose 28-Day Oral Toxicity Study in Rodents; 2008b.

51. Kamsu GT, Fodouop SPC, Tagne RS, Kodjio N, Fakam ALN, Gatsing D. Evaluation of the acute and sub-chronic toxicity of the ethanolic extract of *Curcuma longa* (Zingiberaceae) in wistar albino rats. Mod Chem Appl. 2019;7:267.

52. Di Fiore MSH. Atlas of Human Histology. 2nd ed. Philadelphia: Lea and Febiger; 1963.

53. Ibewuike JC, Ogundaini AO, Ogungbamila FO, Martin M-T, Gallard J-F, Bohlin L, Païs M. Piliostigmin, a 2-phenoxychromone, and C-methylflavonols from *Bauhinia thonningii*. Phytochemistry. 1996;43(3):687–90.

54. Mahato SB, Kundu AP. 13C NMR spectra of pentacyclic triterpenoids: a compilation and some salient features. Phytochemistry. 1994;37(6):1517–75.

55. Waleguele CC, Mba'ning BM, Awantu AF, Bankeu JJK, Fongang YSF, Ngouela AS, Tsamo E, Sewald N, Lenta BN, Krause RWM. Antiparasitic constituents of *Beilschmiedia louisii* and beilschmiedia obscura and some semisynthetic derivatives (Lauraceae). Molecules. 2020;25(12):2862.

56. Navolanic PM, Steelman LS, McCubrey JA. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol. 2003;22(2):237–52.

57. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21–6.

58. Yan GE, Efferth T. Broad-spectrum Cross-resistance to Anticancer Drugs Mediated by Epidermal Growth Factor Receptor. Anticancer Res. 2019;39(7):3585–93.

59. Yan Y, Qing Y, Pink JJ, Gerson SL. Loss of uracil DNA glycosylase selectively resensitizes p53-mutant and -deficient cells to 5-FdU. Mol Cancer Res. 2018;16(2):212–21.

60. Efferth T, Kadioglu O, Saeed MEM, Seo EJ, Mbaveng AT, Kuete V. Medicinal plants and phytochemicals against multidrug-resistant tumor cells

expressing ABCB1, ABCG2, or ABCB5: a synopsis of 2 decades. Phytochem Rev. 2021;20(1):7–53.

61. Kuete V, Efferth T. African flora has the potential to fight multidrug resistance of cancer. Biomed Res Int. 2015;2015: 914813.

62. Boik J. Natural compounds in cancer therapy. Minnesota USA: Oregon Medical Press; 2001.

63. Brahemi G, Kona FR, Fiasella A, Buac D, Soukupova J, Brancale A, Burger AM, Westwell AD. Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer. J Med Chem. 2010;53(7):2757–65.

64. Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E, Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis. 2002;28(2):160–8.

65. Mbaveng AT, Damen F, Celik I, Tane P, Kuete V, Efferth T. Cytotoxicity of the crude extract and constituents of the bark of *Fagara tessmannii* towards multi-factorial drug resistant cancer cells. J Ethnopharmacol. 2019;235:28–37.

66. Shyu MH, Kao TC, Yen GC. Oleanolic acid and ursolic acid induce apoptosis in HuH7 human hepatocellular carcinoma cells through a mitochondrial-dependent pathway and downregulation of XIAP. J Agric Food Chem. 2010;58(10):6110–8.

67. Gu G, Barone I, Gelsomino L, Giordano C, Bonofiglio D, Statti G, Menichini F, Catalano S, Andò S. *Oldenlandia diffusa* extracts exert antiproliferative and apoptotic effects on human breast cancer cells through ERα/Sp1-mediated p53 activation. J Cell Physiol. 2012;227(10):3363–72.

68. Kim SH, Choi KC. Anti-cancer effect and underlying mechanism(s) of kaempferol, a phytoestrogen, on the regulation of apoptosis in diverse cancer cell models. Toxicol Res. 2013;29(4):229–34.

69. Kuete V. 21 - Health Effects of Alkaloids from African Medicinal Plants. In: Toxicological Survey of African Medicinal Plants. edn. Edited by Kuete V. Oxford: Elsevier; 2014:611–33.

70. Mbaveng AT, Hamm R, Kuete V. 19 - Harmful and protective effects of terpenoids from african medicinal plants. In: Toxicological Survey of African Medicinal Plants. edn. Edited by Kuete V. Oxford: Elsevier; 2014:557–76.

71. Delongeas JL, Burnel D, Netter P, Grignon M, Mur JM, Royer RJ, Grignon G. Toxicity and pharmacokinetics of zirconium oxychloride in mice and rats. J Pharmacol. 1983;14(4):437–47.

72. Olela B, Mbaria J, Wachira T, Moriasi G. Acute oral toxicity and anti-inflammatory and analgesic effects of aqueous and methanolic stem bark extracts of *Bauhinia thonningii* (Schumach.). Evid Based Complement Alternat Med. 2020; 2020:5651390.

73. Raji RO, Muhammad HL, Abubakar A, Maikai SS, Raji HF. Acute and sub-acute toxicity profile of crude extract and fractions of *Gymnema sylvestre*. Clinical Phytoscience. 2021;7(1):56.

74. Yakubu MT, Akanji MA, Oladiji AT. Hematological evaluation in male albino rats following chronic administration of aqueous extract of *Fadogia agrestis* stem. Pharmacogn Mag. 2007;3(9):34–8.

75. Costa-Silva JH, Lyra MM, Lima CR, Arruda VM, Araújo AV. Ribeiro e Ribeiro A, Arruda AC, Fraga MC, Lafayette SS, Wanderley AG: A toxicological evaluation of the effect of *Carapa guianensis* Aublet on pregnancy in Wistar rats. J Ethnopharmacol. 2007;112(1):122–6.

76. Bessaguet F, Desmoulière A. Les reins. Actual Pharm. 2020;59(595–596):57–60.

77. Jain R, Stone JA, Agarwal G, Andrade JG, Bacon SL, Bajaj HS, Baker B, Cheng G, Dannenbaum D, Gelfer M, et al. Ligne directrice C-CHANGE pour l'harmonisation des lignes directrices nationales de prévention et de prise en charge des maladies cardiovasculaires en contexte de soins primaires au Canada: mise à jour 2022. Can Med Assoc J. 2023;195(1):E21–42.

78. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8: e1000412.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.